Cargando…

Safety of re‐challenging adults with acute lymphoblastic leukemia with PEG‐asparaginase‐induced severe hypertriglyceridemia when treated with a pediatric‐inspired regimen

PEG‐asparaginase is used as a treatment for Philadelphia‐negative acute lymphoblastic leukemia. In pediatric studies, triglycerides (TGs) were affected more by PEG‐asparaginase than by native L‐asparaginase (10.0% vs. 5.5%). We conducted a retrospective study to determine the safety of re‐challengin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al Nabhani, Ibrahim, Andrews, Claire, Sibai, Jad, Atenafu, Eshetu, Young, Taylor, Chan, Steven M., Gupta, Vikas, Maze, Dawn, Schimmer, Aaron D., Schuh, Andre C., Yee, Karen, Sibai, Hassan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Short Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928666/ https://www.ncbi.nlm.nih.gov/pubmed/36819167 http://dx.doi.org/10.1002/jha2.607

Ejemplares similares

P385: COMPARISON OF CLINICAL OUTCOMES AND ADVERSE EVENTS IN OLDER ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH NATIVE VS PEGYLATED ASPARAGINASE
por: Agustina Perusini, Maria, et al.
Publicado: (2023)

Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL Regimen
por: Chen, Ruiqi, et al.
Publicado: (2020)

PB1768: IS NATIVE E-COLI OR PEG-ASPERAGINASE FORMULATION A HIGHER RISK FOR VTE DEVELOPMENT IN PATIENTS WITH POST TREATMENT ACUTE LYMPHOBLASTIC LEUKEMIA? A META-ANALYSIS
por: Seki, J. T., et al.
Publicado: (2022)

Case Report: Genetic Analysis of PEG-Asparaginase Induced Severe Hypertriglyceridemia in an Adult With Acute Lymphoblastic Leukaemia
por: Iannuzzi, Arcangelo, et al.
Publicado: (2022)

PEG-asparaginase in BFM-90 regimen improves outcomes in adults with newly diagnosed lymphoblastic lymphoma
por: Zheng, Wen, et al.
Publicado: (2017)

Case report: Hyperosmolar hyperglycemic syndrome secondary to PEG-asparaginase-induced hypertriglyceridemia and pancreatitis
por: Mudd, Todd William, et al.
Publicado: (2023)

ODP155 Successful Treatment of PEG-Asparaginase Related Hypertriglyceridemia with Omega-3 Acid Ethyl Esters
por: Radovanovic, Natasa, et al.
Publicado: (2022)

Measurable residual disease monitoring provides insufficient lead-time to prevent morphological relapse in the majority of patients with core-binding factor acute myeloid leukemia
por: Puckrin, Robert, et al.
Publicado: (2020)

Foot gangrene following Tagraxofusp treatment for blastic plasmacytoid dendritic cell neoplasm: Case report
por: Sibai, Jad, et al.
Publicado: (2022)

PEG-asparaginase and native Escherichia coli L-asparaginase in acute lymphoblastic leukemia in children and adolescents: a systematic review
por: Medawar, Camile Valle, et al.
Publicado: (2020)

Efficacy and safety of PEG-asparaginase versus E. coli L-asparaginase in Chinese children with acute lymphoblastic leukemia: a meta-analysis
por: Dai, Zhan-Jing, et al.
Publicado: (2021)

Pediatric-inspired regimen with late intensification and increased dose of L-asparaginase for adult acute lymphoblastic leukemia: the KALLA 1406/1407 study
por: Baek, Dong Won, et al.
Publicado: (2021)

Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia
por: Underwood, Brynne, et al.
Publicado: (2020)

Osteolytic lesion in polycythemia vera: First report and review of literature
por: Cheung, Verna, et al.
Publicado: (2022)

Retrospective cohort study monitoring PEG-asparaginase activity in acute lymphoblastic leukemia patients with and without premedication
por: Losasso, Michael, et al.
Publicado: (2020)

Asparaginase-Induced Hypertriglyceridemia Presenting as Pseudohyponatremia during Leukemia Treatment
por: Hinson, Ashley, et al.
Publicado: (2014)

Diabetic ketoacidosis following PEG-asparaginase therapy
por: Ahmad, Miriam Hinaa, et al.
Publicado: (2018)

Peg-Grafted Liposomes for L-Asparaginase Encapsulation
por: de Souza Guimarães, Marina, et al.
Publicado: (2022)

Use of PEG-asparaginase in newly diagnosed adults with standard-risk acute lymphoblastic leukemia compared with E. coli-asparaginase: a retrospective single-center study
por: Liu, Wen-jian, et al.
Publicado: (2016)

Impact of mutations on pregnancy outcome in patients with myeloproliferative neoplasms
por: Maze, Dawn, et al.
Publicado: (2022)

Case Report: The Use of Intravenous SMOFlipid Infusion to Treat Severe Asparaginase-Induced Hypertriglyceridemia in Two Pediatric Acute Lymphoblastic Leukemia Patients
por: Lau, Sie Chong Doris, et al.
Publicado: (2021)

Pharmacogenetics of asparaginase in acute lymphoblastic leukemia
por: Abaji, Rachid, et al.
Publicado: (2019)

Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
por: Maese, Luke, et al.
Publicado: (2022)

P1020: SCREENING FOR PORTAL HYPERTENSION IN PATIENTS WITH PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
por: Davidson, M., et al.
Publicado: (2022)

SAT-LB91 Asparaginase Induced Severe Hypertriglyceridemia Requiring Multiple Plasmapheresis Sessions
por: Aftab, Hassaan, et al.
Publicado: (2020)

PB1742: FEASIBILITY AND EFFICACY OF A PEG-ASPARAGINASE-BASED TREATMENT PROTOCOL IN ELDERLY PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS
por: Vernarecci, Chiara, et al.
Publicado: (2023)

Rationale for a Pediatric-Inspired Approach in the Adolescent and Young Adult Population with Acute Lymphoblastic Leukemia, with a Focus on Asparaginase Treatment
por: Rizzari, Carmelo, et al.
Publicado: (2014)

L-Asparaginase induced thrombosis in acute lymphoblastic leukemia
por: Kulkarni, Ketan P.
Publicado: (2012)

Asparaginase-associated toxicity in children with acute lymphoblastic leukemia
por: Hijiya, Nobuko, et al.
Publicado: (2016)

L-asparaginase in the treatment of patients with acute lymphoblastic leukemia
por: Egler, Rachel A., et al.
Publicado: (2016)

L-carnitine and Vitamin B Complex for PEG-L-asparaginase-Induced Hepatotoxicity
por: Arora, Sumant, et al.
Publicado: (2019)

Mechanistic studies of PEG-asparaginase-induced liver injury and hepatic steatosis in mice
por: Kumar, Gundala Venkata Naveen, et al.
Publicado: (2021)

Monitoring of asparagine depletion and anti-l-asparaginase antibodies in adult acute lymphoblastic leukemia treated in the pediatric-inspired GRAALL-2005 trial
por: Paillassa, Jérôme, et al.
Publicado: (2018)

Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children With Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study Protocol
por: Rizzari, Carmelo, et al.
Publicado: (2023)

Acute pancreatitis following L-asparaginase in acute lymphoblastic leukemia
por: M'harzi, Soulaimane, et al.
Publicado: (2022)

Our Experiences with Asparaginase Activity Measurements in Children with Lymphoblastic Diseases
por: Müller, Judit, et al.
Publicado: (2023)

Re-examining the Meis Trial for Evidence of False-Positive Results
por: Sibai, Baha, et al.
Publicado: (2020)

Clinical Utility of Next-generation Sequencing in the Management of Myeloproliferative Neoplasms: A Single-Center Experience
por: Alduaij, Waleed, et al.
Publicado: (2018)

Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli‐Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia
por: Vrooman, Lynda M., et al.
Publicado: (2015)

Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia
por: Avramis, Vassilios I, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_jeb5bmj0jiio26hr2j7c2edsoq